

DOCTORAL THESIS

High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1.

(StageII/III 胃癌における *gamma-glutamyl hydrolase (GGH)* および *folylpolyglutamate synthetase (FPGS)* 遺伝子発現の臨床的有用性)

March, 2020

(2020 年 3 月)

Yukio Maezawa

前澤 幸男

Department of Surgery

Yokohama City University School of Medicine

横浜市立大学 大学院医学研究科 医科学専攻 外科治療学

(Doctoral Supervisor: Munetaka Masuda, Professor)

(指導教員：益田 宗孝 教授)



High gamma-glutamyl hydrolase and low folypolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administered postoperative adjuvant chemotherapy with S-1

Yukio Maezawa^{1,5} · Kentaro Sakamaki² · Naohide Oue³ · Yayoi Kimura⁴ · Itaru Hashimoto^{1,5} · Kentaro Hara^{1,5} · Kazuki Kano¹ · Toru Aoyama⁵ · Yukihiro Hiroshima¹ · Takanobu Yamada¹ · Naoto Yamamoto¹ · Takashi Ogata¹ · Hiroyuki Ito⁶ · Haruhiko Cho^{5,7} · Manabu Shiozawa¹ · Takaki Yoshikawa^{5,8} · Soichiro Morinaga¹ · Yasushi Rino⁵ · Wataru Yasui³ · Munetaka Masuda⁵ · Yohei Miyagi⁹ · Takashi Oshima¹

Received: 14 September 2019 / Accepted: 15 November 2019
© The Author(s) 2019

Abstract

Purpose The enzymes gamma-glutamyl hydrolase (GGH) and folypolyglutamate synthetase (FPGS) regulate intracellular folate concentrations needed for cell proliferation, DNA synthesis, and repair. High GGH expression affects 5-FU thymidylate synthase (TS) inhibition and is a risk factor for various malignancies. Here, the clinical significance of *GGH* and *FPGS* expression was investigated in Stage II/III gastric cancer patients undergoing postoperative adjuvant chemotherapy with S-1.

Methods Surgical specimens of cancer tissue and adjacent normal mucosa, obtained from 253 patients with previously untreated gastric cancer, were examined. *GGH* and *FPGS* mRNA expression was measured by qPCR to evaluate their clinicopathological significance in gastric cancer patients after curative resection.

Results While *FPGS* expression showed no significant differences between the cancerous and normal samples, *GGH* expression was higher in cancer tissue than in adjacent normal mucosa. High *GGH* expression was correlated with age, histological type, and vascular invasion. Overall survival (OS) of patients with high *GGH* mRNA expression was significantly poorer than of patients with low *GGH* expression. Multivariate analysis showed that high GGH expression was an independent prognostic factor of OS (HR: 2.58, 95% CI 1.29–5.16). Patients who received S-1 adjuvant treatment showed a significantly poor OS between high *GGH*/low *FPGS* and low *GGH*/high *FPGS*. Patients without adjuvant treatment showed no significant difference.

Conclusion *GGH* expression was significantly higher in gastric cancer tissue than in adjacent normal mucosa. High *GGH* and low *FPGS* expression is a useful independent predictor of poor outcomes in stage II/III gastric cancer patients undergoing postoperative adjuvant chemotherapy with S-1.

Keywords Gastric cancer · Gamma-glutamyl hydrolase (GGH) · Folylpolyglutamate synthetase (FPGS) · S-1 · Prognostic factor

Introduction

Gastric cancer was the fifth most common in new cases of cancer (1,033,701 cases) and the third most common in cancer-related deaths (781,631 deaths) in 2018 (Bray et al. 2018). Curative resection and postoperative adjuvant

chemotherapy is the standard treatment for locally advanced gastric cancer in Japan. Since Adjuvant Chemotherapy Trial of S-1 for Gastric Cancer (ACTS-GC), adjuvant chemotherapy with S-1 is one of the standard treatments for pathological TNM stage II/III gastric cancer (except pT1N2-3/pT3N0) for the prevention of recurrence (Sakuramoto et al. 2007; Japanese gastric cancer treatment guidelines 2014 (ver. 4) 2017). Moreover, CLASSIC and JACCRO-07 trials have been used to confirm the effectiveness of capecitabine plus oxaliplatin (CapeOX) therapy and S-1 plus docetaxel

✉ Takashi Oshima
oshimat@kcch.jp

Extended author information available on the last page of the article

(DS) therapy; fluoropyrimidine is still the key drug used in the postoperative adjuvant chemotherapy for gastric cancer (Sakuramoto et al. 2007; Bang et al. 2012; Noh et al. 2014). However, the outcomes of treatment are still insufficient, as recurrence occurs in 20–60% of patients, even after a complete resection and the administration of the appropriate adjuvant therapy (Maehara et al. 2000; Rivera et al. 2007). The personalization of postoperative adjuvant chemotherapy treatment using biomarkers is a promising strategy to improve the survival of patients with localized advanced gastric cancer. However, a specific biomarker for use in predicting the therapeutic effects of fluorinated pyrimidine and the long-term outcomes of patients with locally advanced gastric cancer has yet to be identified (Pizzorno et al. 1988; Shubbar et al. 2013; Melling et al. 2017).

Folic acid is a molecule which is necessary for cell proliferation, DNA synthesis, and repair. Gamma-glutamyl hydroxylase (GGH) and folypolyglutamate synthetase (FPGS) are enzymes which regulate intracellular folate concentrations (Bailey 2010). GGH promotes the production of monoglutamyl acid folate, a metabolite of folic acid required for DNA synthesis. On the other hand, FPGS catalyzes the hydrolysis of monoglutamate folate into polyglutamate, which has a high intracellular retention (Bailey 2010). Thus, GGH and FPGS strongly influence DNA synthesis in cancer cells.

Previous studies have reported that high GGH expression is a risk factor for the prognosis of various malignancies (Shubbar et al. 2013; Melling et al. 2017). Moreover, the expression of GGH and FPGS was reported to affect thymidylate synthase (TS) inhibition of 5-fluorouracil (5-FU) in a range of malignancies (Cheradame et al. 1997; Sakamoto et al. 2008; Kim et al. 2013). Recently, it was reported that high GGH expression is a risk factor of lymph node recurrence after surgery in patients with stage II/III gastric cancer, using clinical specimens of ACTS-GC (Terashima et al. 2017). However, the relationship between the expression of GGH and FPGS and the effect of S-1 in adjuvant chemotherapy has not yet been evaluated. In this study, we examined the clinical significance of GGH and FPGS expression in patients with stage II/III gastric cancer who were undertaking postoperative adjuvant chemotherapy with S-1.

Materials and methods

Patients and samples

We studied surgical specimens of cancer tissue and adjacent normal mucosa obtained from 253 patients with gastric cancer undergoing gastrectomy as the first treatment. The patients underwent surgery at the Department of Surgery (Yokohama City University), the Gastroenterological Center (Yokohama City Medical Center), and the Department of

Gastrointestinal surgery (Kanagawa Cancer Center) between March 2002 and July 2012. Informed consent was obtained from each patient, with all protocols approved by the ethics committees of each institute before the initiation of the study. All tissue samples were embedded in O.C.T. compound (Sakura Finetechnical Co., Ltd., Tokyo) and immediately stored at -80°C until further use. None of the patients had any other malignancies. The specimens were stained with hematoxylin and eosin and examined histopathologically. Sections consisting of $>80\%$ cancer cells were used to prepare total RNA.

Quantitative reverse-transcriptase polymerase chain reaction (qRT-PCR)

qRT-PCR was performed with iQ SYBR Green Supermix (Bio-Rad Laboratories). PCR was carried out in a total volume of 15 μl , which included 0.2 μg of cDNA derived from 75 ng of RNA, 0.4 μM of each primer, 7.5 μl of iQ SYBR Green Supermix containing dATP, dCTP, dGTP, and dTTP at concentrations of 400 μM each, as well as 50 units/ml of iTaq DNA polymerase. The PCR cycles consisted of 3 min at 95°C , followed by 40 cycles of denaturation of the cDNA for 10 s at 95°C , annealing for 10 s, a primer extension for 20 s at 72°C , followed by 10 min at 72°C . The annealing temperature was set at 57°C and 59°C for GGH and FPGS, respectively. To distinguish specific from nonspecific products and primer dimers, melting curve analyses were performed. To evaluate the specific mRNA expression in the samples, a standard curve was produced for each run, measuring three points of the human control cDNA (Clontech Laboratories, Inc., CA, USA). The concentration of each sample was calculated by relating its crossing point to a standard curve. The measurement was performed three times and the average value was adopted. The PCR primer sequences of GGH, FPGS and β -actin, used as an internal control, are shown in Table 1.

Statistical analysis

Gene expression levels were compared between gastric cancer and adjacent normal mucosa by the Wilcoxon test. The expression levels of *GGH* and *FPGS* mRNA were categorized as low or high based on a cut-off value calculated using the maximum Chi-square (χ^2) test. The relationship between mRNA expression and potential explanatory variables, including age, gender, tumor size, depth of invasion, lymph-node metastasis, distant metastasis, stage, lymphatic invasion, venous invasion, and histological type, were evaluated with the χ^2 test. The associations between the expression of *GGH* and *FPGS* mRNA and survival were assessed using the Kaplan–Meier method, then compared using the log-rank test. A Cox proportional-hazards

Table 1 PCR primers and conditions

Gene	Primer	Annealing temperature (°C)	Product size (bp)
<i>GGH</i>			
Sense	5'-AGTTGCGTTACACCCTTTCTTGAC-3'	57	151
Antisense	5'-GCTCGCTCCAACCGACTGC-3'		
<i>FPGS</i>			
Sense	5'-TTCCGCTTCCTGACACTC-3'	59	116
Antisense	5'-GGCTTCCTGATGATGTTGG-3'		
<i>β-Actin</i>			
Sense	5'-AGTTGCGTTACACCCTTTCTTGAC-3'	60	171
Antisense	5'-GCTCGCTCCAACCGACTGC-3'		

model was used to perform univariate analyses and step-wise multivariate analyses to determine the risk factors. The software program SPSS (ver. 23.0; IBM Corp., Armonk, NY, USA) was used to perform all the statistical analyses. Two-sided *P* values were calculated, and *P* < 0.05 was defined as a statistically significant difference. Data were expressed as medians (range).

Results

GGH and *FPGS* mRNA expression in gastric cancer tissue and adjacent normal mucosa

The *GGH* mRNA expression levels were higher in cancer tissue (0.478 [0.000–52.951]) than in adjacent normal mucosa (0.000 [0.000–6.597] *P* < 0.001). On the other hand, there was no significant difference in the *FPGS* mRNA expression level between cancer tissue (3.458 [0.000–63.019]) and adjacent normal mucosa (3.295 [0.000–80.960] *P* = 0.67) (Fig. 1a, b).

Relationship of *GGH* and *FPGS* mRNA expression levels to clinicopathological features

The expression levels of the *GGH* and *FPGS* genes were categorized as low or high based on a cut-off value calculated using the maximum Chi-square test. The relationship of the expression level of *GGH* mRNA or *FPGS* mRNA to the clinicopathological features was then examined. The expression level of *GGH* mRNA was related to age, histological type, and vascular invasion. On the other hand, the expression level of *FPGS* mRNA was related to vascular invasion and lymphatic invasion (Table 2).

Uni- and multivariate analysis of the relationship of clinicopathological factors and *GGH*/*FPGS* gene expression levels to overall survival

Univariate Cox regression analyses found that high levels of *GGH* mRNA expression, pathological stage, and lymphatic invasion were the significant prognostic factors. On the other hand, according to multivariate Cox regression analysis, high levels of *GGH* mRNA expression, pathological stage, lymphatic invasion, and no postoperative adjuvant treatment with S-1 were the independent prognostic factors. The expression of *FPGS* mRNA was not selected as a significant prognostic factor (Table 3).


Comparison of overall survival rates by expression levels of *GGH* or *FPGS* mRNA in gastric cancer tissue

The median follow-up time was 1823 days. During this follow-up period, 127 patients died. The 5-year overall survival rate (OS) in patients with low and high levels of *GGH* mRNA expression were 76.8% and 61.8%, respectively (*P* = 0.017, Fig. 2a). The 5-year OS rate in patients with low and high levels of *FPGS* mRNA expression were 59.9% and 65.0%, respectively (*P* = 0.425, Fig. 2b).


Stratified by whether S-1 adjuvant treatment was performed or not, the OS in patients who received S-1 adjuvant treatment was significantly poorer in patients with high levels of *GGH* mRNA expression than those with low levels of *GGH* mRNA expression (*P* = 0.043, Fig. 3a). On the other hand, in patients who underwent surgery alone, there was no significant difference in the OS between patients with high and low level of *GGH* mRNA expression (*P* = 0.21, Fig. 3b).

The 5-year OS in patients with various combinations of *GGH*/*FPGS* expression, that is, low/low, low/high, high/high, and high/low, was 88.9%, 73.6%, 63.5%, and 47.8%, respectively (*P* = 0.019, Fig. 4). Stratified by

Fig. 1 a Comparison of expression levels of the *GGH* gene between gastric cancer tissue and adjacent normal mucosa ($P < 0.001$). **b** Comparison of expression levels of the *FPGS* gene between gastric cancer tissue and adjacent normal mucosa ($P = 0.82$)



	normal	tumor	P value
GGH expression, median (range)	0.000 (0.000-6.597)	0.478 (0.000-52.951)	< 0.001



	normal	tumor	P value
FPGS expression, median (range)	3.458 (0.000-63.019)	3.295 (0.000-80.960)	0.82

whether postoperative adjuvant treatment with S-1 was performed, the OS in patients who received S-1 adjuvant treatment was significantly poorer in patients with high levels of *GGH* mRNA expression and low levels of *FPGS* mRNA expression than those with low levels of

GGH mRNA expression and high levels of *FPGS* mRNA expression ($P = 0.039$, Fig. 5a). On the other hand, there was no significant difference in patients who underwent surgery alone ($P = 0.525$, Fig. 5b).

Table 2 Comparison of patient's background and pathological outcomes

Variables	All Patients (<i>n</i> = 253)	GGH expression		<i>P</i> value	FPGS expression		<i>P</i> value
		High group (<i>n</i> = 211)	Low group (<i>n</i> = 42)		High group (<i>n</i> = 222)	Low group (<i>n</i> = 31)	
Age (years), median (range)	65 (38–98)	70 (48–98)	64 (38–87)	<0.001	68 (44–89)	69 (380–98)	0.46
Gender				0.94			0.25
Male	170 (67.2%)	142 (67.3%)	28 66.7%)		152 (68.5%)	18 (58.1%)	
Female	83 (32.8%)	69 (32.7%)	14 (33.3%)		70 (31.5%)	13 41.9%)	
Histological type				0.012			0.66
Undifferentiated	140 (55.3%)	108 (51.2%)	32 76.2%)		124 (55.9%)	16 (51.6%)	
Differentiated	112 (44.3%)	102 48.3%)	10 (23.8%)		98 (44.1%)	15 (48.4%)	
Tumor size (mm)				0.12			0.84
< 65	135 (53.4%)	108 (51.2%)	27 (64.3%)		119 (53.6%)	16 (51.6%)	
65 ≤	118 (46.6%)	103 (48.8%)	15 (35.7%)		103 (46.4%)	15 (48.4%)	
Pathological <i>T</i> factor				0.80			0.32
T1–3	119 (47.0%)	100 47.4%)	19 (45.2%)		107 (48.2%)	12 (38.7%)	
T4	134 (53.0%)	111 (52.6%)	23 (54.8%)		115 (51.8%)	19 (61.3%)	
Pathological <i>N</i> factor				0.60			0.69
N0	56 (22.1%)	48 (22.75%)	8 (19.1%)		50 (22.5%)	6 (19.4%)	
N1–3	197 (77.9%)	163 (77.3%)	34 (81.0%)		172 (77.5%)	25 (80.6%)	
Stage				0.71			0.59
II	103 (49.7%)	87 (41.2%)	16 (38.1%)		89 (40.1%)	14 (45.2%)	
III	150 (59.3%)	124 (58.8%)	26 (61.9%)		133 (59.9%)	17 (54.8%)	
Vascular invasion				0.028			0.086
v0	73 (28.9%)	55 (26.1%)	18 (42.9%)		60 (27.0%)	13 (41.9%)	
v1–3	180 (71.1%)	156 (73.9%)	24 (57.1%)		162 (73.0%)	18 (58.1%)	
Lymphatic invasion				0.87			0.094
ly0	81 (32.0%)	68 (32.2%)	13 (31.0%)		67 (30.2%)	14 (45.2%)	
ly1–3	172 (68.0%)	143 (67.8%)	29 (69.0%)		155 (69.8%)	17 (54.8%)	
Adjuvant therapy				0.35			0.46
Yes	146 (42.3%)	119 (56.4%)	27 (64.3%)		130 (58.6%)	16 (51.6%)	
No	107 (57.7%)	92 (43.6%)	15 (35.7%)		92 (41.4%)	15 (48.4%)	

Discussion

In this study, we measured the levels of *GGH* and *FPGS* mRNA expression in cancer tissues and adjacent normal mucosa in patients with stage II/III gastric cancer. We then examined the relationship between the expression levels of these genes and the clinicopathological features and long-term outcomes to evaluate the clinical significance of *GGH* and *FPGS* mRNA expression in gastric cancer tissue in patients with Stage II/III gastric cancer undergoing postoperative adjuvant chemotherapy with S-1.

First, the expression levels of *GGH* and *FPGS* mRNA in gastric cancer tissue and adjacent normal mucosa were compared. Several previous studies have compared the relative expression levels of *GGH* and *FPGS* mRNA between various types of cancer tissue and adjacent normal tissue

(Kidd et al. 2005; Pollard et al. 2009; Shubbar et al. 2013). These studies reported that *GGH* mRNA expression was higher in cancer tissue compared to normal tissue in breast cancer (Shubbar et al. 2013) and bladder cancer (Pollard et al. 2009). Our results are consistent with these findings, as the expression levels of *GGH* mRNA were found to be significantly higher in the gastric cancer tissue than in the paired adjacent normal mucosa. As for *FPGS* expression, it has been previously reported that the expression of *FPGS* was higher in cancer tissue than normal mucosa in colorectal cancer (Odin et al. 2003; Kidd et al. 2005). However, in our study, there was no significant difference in the expression levels of *FPGS* mRNA between the cancer tissue and adjacent normal tissue.

Next, the relationship between the expression levels of *GGH* and *FPGS* mRNA and the clinicopathological features

Table 3 Uni- and multivariate Cox proportional-hazards analysis of clinicopathological factors (overall survival)

Characteristics	Number	Univariate			Multivariate		
		HR	95% CI	P value	HR	95% CI	P value
Expression of GGH				0.02			0.006
Low	42	1.00			1.00		
High	211	2.27	1.14–4.51		2.65	1.32–5.31	
Expression of FPGS				0.43			
Low	42	1.00					
High	211	1.27	0.71–2.28				
Age(years)				0.81			
< 65	135	1.00					
65 ≤	118	1.05	0.69–1.62				
Gender				0.16			
Female	83	1.00					
Male	170	1.34	0.88–2.15				
Tumor size (mm)				0.84			
< 65	135	1.00					
65 ≤	118	1.04	0.70–1.57				
Histological type				0.82			
Undifferentiated	140	1.00					
Differentiated	113	1.05	0.70–1.58				
Pathological Stage				<0.001			<0.001
II	103	1.00			1.00		
III	150	2.33	1.47–3.71		2.44	1.50–3.95	
Vascular invasion				0.28			
v0	73	1.00					
v1–3	180	1.29	0.81–2.03				
Lymphatic invasion				0.008			0.011
ly0	81	1.00			1.00		
ly1–3	172	1.91	1.18–3.08		1.94	1.16–3.22	
Adjuvant therapy				0.49			0.018
Yes	146	1.00			1.00		
No	107	1.15	0.77–1.64		1.68	1.09–2.59	

in patients with stage II/III gastric cancer were examined. It was reported that GGH expression was significantly associated with a high histological tumor grade (BRE grade III, $P < 0.001$), as well as ER/PR receptors in patients with breast cancer (Shubbar et al. 2013). As for FPGS, to the best of our knowledge, there are no reports. In this study, high levels of *GGH* mRNA expression were significantly correlated with age, histological type, and vascular invasion. High levels of *FPGS* mRNA expression, on the other hand, were found to be related to vascular invasion and lymphatic invasion.

The relationship between the expression levels of *GGH* and *FPGS* mRNA in cancer tissue and long-term outcomes in patients with stage II/III gastric cancer was then assessed. Several studies have previously reported that patients with high levels of *GGH* mRNA expression in cancer tissue resulted in significantly poor outcomes compared to patients with low levels of *GGH* mRNA expression. Melling et al.

(2017) reported that 10-year recurrence-free survival was significantly higher in patients with high levels of *GGH* expression compared to patients with low level of *GGH* expression in ERG negative prostate cancer ($P = 0.0002$). Shubbar et al. (2013) reported that 8-year disease-specific survival (DSS) was significantly different between patients expressing GGH (39%) and patients whose tumors were GGH-negative (68%, $P = 0.037$) in invasive breast cancer. In addition, univariate analysis showed that GGH expression exhibited a lower DSS probability, with a 2.7-fold increase in risk of death ($P = 0.04$) (Shubbar et al. 2013). As for FPGS, it was reported that 5-year tumor-specific survival (TSS) was significantly better in patients with high levels of *FPGS* mRNA expression (75%) than patients with low levels of *FPGS* mRNA expression (35%, $P = 0.002$). In addition, *FPGS* expression has been previously reported to be an independent significant prognostic factor of TSS in patients with colorectal cancer (Odin et al. 2003).

Fig. 2 **a** Comparison of overall survival between high and low expression levels of the GGH gene in gastric cancer tissue ($P=0.017$). **b** Comparison of overall survival between high and low expression levels of the FPGS gene in gastric cancer tissue ($P=0.425$)




Fig. 3 Comparison of overall survival between high and low expression levels of the GGH gene in gastric cancer tissue stratified by whether S-1 adjuvant treatment was performed or not. **a** Patients who did not receive S-1 adjuvant treatment ($P=0.21$). **b** Patients received S-1 adjuvant treatment ($P=0.043$)






Fig. 4 Comparison of overall survival between high and low expression levels of the *GGH*/*FPGS* gene in gastric cancer tissue ($P=0.019$)





In present study, the 5-year OS was significantly poorer in patients with high levels of *GGH* mRNA expression than in those with low expression levels. In patients with stage II/III gastric cancer who were administrated adjuvant chemotherapy with S-1, although there was no significant difference in the 5-year OS between patients with high and low levels of *FPGS* mRNA expression, the 5-year OS in patients with the combination of high *GGH* mRNA and low *FPGS* mRNA expression levels in cancer tissue was significantly poorer than that in the other patients.

The elucidation of the mechanism whereby high levels of *GGH* expression and low levels of *FPGS* expression could be used as prognostic biomarkers in patients with locally advanced gastric cancer for which the administration of postoperative adjuvant chemotherapy with S-1 is not currently sufficient. Previous reports have suggested the following mechanism: 5-FU is an active ingredient of S-1 that inhibits the action of thymidylate synthase (TS) and suppresses DNA synthesis and cell proliferation by forming a trimer with 5-fluorodeoxyuridylate (Fd-UMP), which is a metabolite of 5-FU (Longley et al. 2003; Wilson et al. 2014). The polyglutamate folate is produced by the folate metabolism and induces the formation of the trimer (Moran 1999). *GGH* promotes the production of monoglutamyl acid folate, a metabolite of folic acid required for DNA synthesis. Meanwhile, *FPGS* catalyzes the hydrolysis of monoglutamyl

folate into polyglutamate, which has a high intracellular retention (Bailey 2010). Thus, high *GGH* and/or low *FPGS* activity reduces 5,10-methylenetetrahydrofolic acid, as well as the TS, which can bind to 5,10-methylenetetrahydrofolic acid. As a result, it is possible that a small amount of 5-FU can exert a TS inhibitory effect in patients with high *GGH* and/or low *FPGS* activity (Moran 1999). These mechanisms indicated that the outcomes of patients with high levels of *GGH* expression and low levels of *FPGS* expression in cancer tissue were poorer than the other patients. Moreover, when combined with our results, these findings suggest that a combination of high *GGH* expression and low *FPGS* expression in cancer tissue could be used as prognostic biomarkers in patients with locally advanced gastric cancer undergoing postoperative adjuvant chemotherapy with S-1 after curative resection.

This study has several limitations. First, the study examined only mRNA expression in gastric cancer tissues. Considering its clinical utility as a biomarker, future studies should examine both mRNA and protein expression levels in the same specimen. Second, there was an issue regarding the heterogeneity of the gastric cancer tissue. The sample from which the mRNA was extracted was a 5-mm square stomach cancer tissue, including the deepest part, which, however, did not completely represent the entire tumor. Third, since *GGH* and *FPGS* have contrasting effects, the

Fig. 5 Comparison of overall survival between high and low expression levels of the GGH/FPGS gene in gastric cancer tissue stratified by whether S-1 adjuvant treatment was performed or not. **a** Patients who did not receive S-1 adjuvant treatment ($P=0.525$). **b** Patients received S-1 adjuvant treatment ($P=0.039$)



prognosis of the high *GGH*/low *FPGS* group could be predicted to be the worst, and, inversely, that of the low *GGH*/high *FPGS* group the best. The present study demonstrated that a significant difference was observed when comparing the OS in the four groups based on different combinations of *GGH* and *FPGS* mRNA expression. In addition, there was an identically significant difference in the OS of the four groups with patients that had received S-1 adjuvant treatment and the analysis of the two groups with high or low *GGH*. Although the obtained result was different from the hypothesis, which stated that the prognosis of the low *GGH*/high *FPGS* group would be the best, the number of low *GGH*/low *FPGS* patients was nine, which may be the cause of the lack of statistical power. As such, it is possible that the combination of *GGH*/*FPGS* mRNA may have an enhanced accuracy as a biomarker.

In conclusion, high levels of *GGH* mRNA expression and low levels of *FPGS* mRNA expression in cancer tissue may be useful predictive biomarkers for the survival of patients with stage II/III gastric cancer undergoing postoperative adjuvant chemotherapy with S-1 after radical resection. It would be interesting for future studies to verify the possibility of personalizing treatments by selecting the appropriate regimen based on the expression levels of *GGH* and *FPGS* for patients with locally advanced gastric cancer in a clinical trial.

Funding No funding.

Compliance with ethical approval

Conflict of interest The authors declare that they have no competing interests.

Ethical approval This policy was in compliance with Helsinki Declaration of 1975.

Informed consent We obtained the informed consent from all patients who entered into the present study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.


References

- Bailey LB (2010) Folate in health and disease. CRC Press, Cambridge
- Bang YJ et al (2012) Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. *Lancet* (London, England) 379:315–321. [https://doi.org/10.1016/s0140-6736\(11\)61873-4](https://doi.org/10.1016/s0140-6736(11)61873-4)
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin* 68:394–424. <https://doi.org/10.3322/caac.21492>
- Cheradame S, Etienne MC, Chazal M, Guillot T, Fischel JL, Formento P, Milano G (1997) Relevance of tumoral folylpolyglutamate synthetase and reduced folates for optimal 5-fluorouracil efficacy: experimental data. *Eur J Cancer* (Oxford, England: 1990) 33:950–959
- Japanese Gastric Cancer Association (2017) Japanese gastric cancer treatment guidelines 2014 (ver. 4). *Gastric Cancer* 20:1–19. <https://doi.org/10.1007/s10120-016-0622-4>
- Kidd EA, Yu J, Li X, Shannon WD, Watson MA, McLeod HL (2005) Variance in the expression of 5-fluorouracil pathway genes in colorectal cancer. *Clin Cancer Res* 11:2612–2619. <https://doi.org/10.1158/1078-0432.ccr-04-1258>
- Kim SE et al (2013) Gamma-glutamyl hydrolase modulation and folate influence chemosensitivity of cancer cells to 5-fluorouracil and methotrexate. *Br J Cancer* 109:2175–2188. <https://doi.org/10.1038/bjc.2013.579>
- Longley DB, Harkin DP, Johnston PG (2003) 5-fluorouracil: mechanisms of action and clinical strategies. *Nat Rev Cancer* 3:330–338. <https://doi.org/10.1038/nrc1074>
- Maehara Y, Hasuda S, Koga T, Tokunaga E, Kakeji Y, Sugimachi K (2000) Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer. *Br J Surg* 87:353–357. <https://doi.org/10.1046/j.1365-2168.2000.01358.x>
- Melling N et al (2017) High-level gamma-glutamyl-hydrolase (*GGH*) expression is linked to poor prognosis in ERG negative prostate cancer. *Int J Mol Sci*. <https://doi.org/10.3390/ijms18020286>
- Moran RG (1999) Roles of folylpoly-gamma-glutamate synthetase in therapeutics with tetrahydrofolate antimetabolites: an overview. *Semin Oncol* 26:24–32
- Noh SH et al (2014) Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. *Lancet Oncol* 15:1389–1396. [https://doi.org/10.1016/s1470-2045\(14\)70473-5](https://doi.org/10.1016/s1470-2045(14)70473-5)
- Odin E et al (2003) Altered gene expression of folate enzymes in adjacent mucosa is associated with outcome of colorectal cancer patients. *Clin Cancer Res* 9:6012–6019
- Pizzorno G et al (1988) Impaired polyglutamylolation of methotrexate as a cause of resistance in CCRF-CEM cells after short-term, high-dose treatment with this drug. *Cancer Res* 48:2149–2155
- Pollard C, Nitz M, Baras A, Williams P, Moskaluk C, Theodorescu D (2009) Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. *Am J Pathol* 175:1824–1830. <https://doi.org/10.2353/ajpath.2009.090155>
- Rivera F, Vega-Villegas ME, Lopez-Brea MF (2007) Chemotherapy of advanced gastric cancer. *Cancer Treat Rev* 33:315–324. <https://doi.org/10.1016/j.ctrv.2007.01.004>
- Sakamoto E et al (2008) Folylpolylglutamate synthase and gamma-glutamyl hydrolase regulate leucovorin-enhanced 5-fluorouracil anticancer activity. *Biochem Biophys Res Commun* 365:801–807. <https://doi.org/10.1016/j.bbrc.2007.11.043>
- Sakuramoto S et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. *N Engl J Med* 357:1810–1820. <https://doi.org/10.1056/nejmoa072252>
- Shubbar E, Helou K, Kovacs A, Nemes S, Hajizadeh S, Enerback C, Einbeigi Z (2013) High levels of gamma-glutamyl hydrolase (*GGH*) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer. *BMC Cancer* 13:47. <https://doi.org/10.1186/1471-2407-13-47>
- Terashima M et al (2017) TOP2A, *GGH*, and *PECAM1* are associated with hematogenous, lymph node, and peritoneal recurrence in stage II/III gastric cancer patients enrolled in the ACTS-GC study. *Oncotarget* 8:57574–57582. <https://doi.org/10.18632/oncotarget.15895>
- Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD (2014) Standing the test of time: targeting thymidylate biosynthesis in

cancer therapy. *Nat Rev Clin Oncol* 11:282–298. <https://doi.org/10.1038/nrclinonc.2014.51>

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Affiliations

Yukio Maezawa^{1,5} · Kentaro Sakamaki² · Naohide Oue³ · Yayoi Kimura⁴ · Itaru Hashimoto^{1,5} · Kentaro Hara^{1,5} · Kazuki Kano¹ · Toru Aoyama⁵ · Yukihiro Hiroshima¹ · Takanobu Yamada¹ · Naoto Yamamoto¹ · Takashi Ogata¹ · Hiroyuki Ito⁶ · Haruhiko Cho^{5,7} · Manabu Shiozawa¹ · Takaki Yoshikawa^{5,8} · Soichiro Morinaga¹ · Yasushi Rino⁵ · Wataru Yasui³ · Munetaka Masuda⁵ · Yohei Miyagi⁹ · Takashi Oshima¹ 

¹ Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan

² Department of Biostatistics Informatics, Graduate School of Medicine, The University of Tokyo, Tokyo 113-8658, Japan

³ Department of Molecular Pathology, Hiroshima University Institute of Biomedical and Health Science, Hiroshima 734-8551, Japan

⁴ Advanced Medical Research Center, Yokohama City University, Yokohama, Kanagawa 236-0004, Japan

⁵ Department of Surgery, Yokohama City University, Yokohama, Kanagawa 236-0004, Japan

⁶ Department of Thoracic Surgery, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan

⁷ Department of Surgery, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Bunkyo-ku, Tokyo 113-8677, Japan

⁸ Department of Gastric Surgery, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan

⁹ Kanagawa Cancer Center Research Institute, Yokohama, Kanagawa 241-8515, Japan

論文目録

I 主論文

Maezawa, Y., Sakamaki, K., Oue, N., Kimura, Y., Hashimoto, I., Hara, K., Kano, K., Aoyama, T., Hiroshima, Y., Yamada, T., Yamamoto, N., Ogata, T., Ito, H., Cho, H., Shiozawa, M., Yoshikawa, T., Morinaga, S., Rino, Y., Yasui, W., Masuda, M., Miyagi, Y. & Oshima, T. 2019. High gamma-glutamyl hydrolase and low folylpolyglutamate synthetase expression as prognostic biomarkers in patients with locally advanced gastric cancer who were administrated postoperative adjuvant chemotherapy with S-1. *J Cancer Res Clin Oncol*.

II 副論文

なし

III 参考論文 (英文)

Aoyama, T., Maezawa, Y., Yoshikawa, T., Segami, K., Kano, K., Hayashi, T., Yamada, T., Numata, M., Goda, M., Tamagawa, H., Sato, T., Yukawa, N., Rino, Y., Masuda, M., Ogata, T., Cho, H. & Oshima, T. 2019a. Comparison of Weight and Body Composition After Gastrectomy Between Elderly and Non-elderly Patients With Gastric Cancer. *In Vivo*, 33(1), pp 221-227.

Aoyama, T., Sato, T., Maezawa, Y., Kano, K., Hayashi, T., Yamada, T., Yukawa, N., Oshima, T., Rino, Y., Masuda, M., Ogata, T., Cho, H. & Yoshikawa, T. 2017. Postoperative weight loss leads to poor survival through poor S-1 efficacy in patients with stage II/III gastric cancer. *Int J Clin Oncol*, 22(3), pp 476-483.

Aoyama, T., Sato, T., Segami, K., Maezawa, Y., Kano, K., Kawabe, T., Fujikawa, H., Hayashi, T., Yamada, T., Tsuchida, K., Yukawa, N., Oshima, T., Rino, Y., Masuda, M., Ogata, T., Cho, H. & Yoshikawa, T. 2016. Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer. *Ann Surg Oncol*, 23(6), pp 1963-70.

Aoyama, T., Yoshikawa, T., Maezawa, Y., Kano, K., Hara, K., Sato, T., Hayashi, T., Yamada, T., Cho, H., Ogata, T., Tamagawa, H., Yukawa, N., Rino, Y., Masuda, M. & Oshima, T. 2018. A Comparison of the Body Composition Changes Between Laparoscopy-assisted and Open Total Gastrectomy for Gastric Cancer. *In Vivo*, 32(6), pp 1513-1518.

Aoyama, T., Yoshikawa, T., Maezawa, Y., Kano, K., Numata, M., Hara, K., Komori, K., Yamada, T., Hayashi, T., Sato, T., Tamagawa, H., Yukawa, N., Rino, Y., Masuda, M., Ogata, T., Cho, H. &

Oshima, T. 2019b. The postoperative lean body mass loss at one month leads to a poor survival in patients with locally advanced gastric cancer. *J Cancer*, 10(11), pp 2450-2456.

Aoyama, T., Yoshikawa, T., Maezawa, Y., Segami, K., Kano, K., Numata, M., Yamada, T., Tamagawa, H., Fujikawa, H., Komori, K., Hayashi, T., Sato, T., Yukawa, N., Rino, Y., Masuda, M., Ogata, T., Cho, H. & Oshima, T. 2019c. Influence of Postoperative Surgical Complications After Gastrectomy on Body Weight and Body Composition Changes in Patients With Gastric Cancer. *Anticancer Res*, 39(2), pp 1073-1078.

Hashimoto, I., Sakamaki, K., Oue, N., Kimura, Y., Hiroshima, Y., Hara, K., Maezawa, Y., Kano, K., Aoyama, T., Yamada, T., Yamamoto, N., Ogata, T., Ito, H., Shiozawa, M., Morinaga, S., Rino, Y., Yasui, W., Masuda, M., Miyagi, Y. & Oshima, T. 2019. Clinical Significance of PRKCI Gene Expression in Cancerous Tissue in Patients With Gastric Cancer. *Anticancer Res*, 39(10), pp 5715-5720.

Ishida, H., Cho, H., Tsuchida, K., Onoyama, H. & Maezawa, Y. 2019. Laparoscopic stomach-partitioning gastrojejunostomy in preparation for distal gastrectomy and Billroth-II reconstruction after neoadjuvant chemotherapy for advanced gastric cancer with gastric outlet obstruction: A case report. *Asian J Endosc Surg*.

Kano, K., Aoyama, T., Maezawa, Y., Hayashi, T., Yamada, T., Tamagawa, H., Sato, T., Cho, H., Yoshikawa, T., Rino, Y., Masuda, M., Oshima, T. & Ogata, T. 2019. Postoperative Level of C-Reactive Protein Is a Prognosticator After Esophageal Cancer Surgery With Perioperative Steroid Therapy and Enhanced Recovery After Surgery Care. *In Vivo*, 33(2), pp 587-594.

Kano, K., Aoyama, T., Maezawa, Y., Nakajima, T., Ikeda, K., Yamada, T., Sato, T., Oshima, T., Rino, Y., Masuda, M., Ogata, T., Cho, H. & Yoshikawa, T. 2017a. The survival and prognosticators of peritoneal cytology-positive gastric cancer patients who received upfront gastrectomy and subsequent S-1 chemotherapy. *Int J Clin Oncol*, 22(5), pp 887-896.

Kano, K., Aoyama, T., Nakajima, T., Maezawa, Y., Hayashi, T., Yamada, T., Sato, T., Oshima, T., Rino, Y., Masuda, M., Cho, H., Yoshikawa, T. & Ogata, T. 2017b. Prediction of postoperative inflammatory complications after esophageal cancer surgery based on early changes in the C-reactive protein level in patients who received perioperative steroid therapy and enhanced recovery after surgery care: a retrospective analysis. *BMC Cancer*, 17(1), pp 812.

Kano, K., Aoyama, T., Yoshikawa, T., Maezawa, Y., Nakajima, T., Hayashi, T., Yamada, T., Sato, T., Oshima, T., Rino, Y., Masuda, M., Cho, H. & Ogata, T. 2018. The Negative Survival Impact of Infectious Complications After Surgery is Canceled Out by the Response of Neoadjuvant Chemotherapy in Patients with Esophageal Cancer. *Ann Surg Oncol*, 25(7), pp 2034-2043.

Maezawa, Y., Aoyama, T., Kano, K., Tamagawa, H., Numata, M., Hara, K., Murakawa, M., Yamada, T., Sato, T., Ogata, T., Oshima, T., Yukawa, N., Yoshikawa, T., Masuda, M. & Rino, Y. 2019. Impact of the Age-adjusted Charlson comorbidity index on the short- and long-term outcomes of patients undergoing curative gastrectomy for gastric cancer. *J Cancer*, 10(22), pp 5527-5535.

Maezawa, Y., Aoyama, T., Yamada, T., Kano, K., Hayashi, T., Sato, T., Oshima, T., Rino, Y., Masuda, M., Ogata, T., Cho, H. & Yoshikawa, T. 2017. Priority of lymph node dissection for proximal gastric cancer invading the greater curvature. *Gastric Cancer*.

Numata, M., Hasuo, K., Hara, K., Maezawa, Y., Kazama, K., Inari, H., Takata, K., Jin, Y., Yukawa, N., Oshima, T., Rino, Y., Taguri, M. & Masuda, M. 2015. A propensity score-matching analysis comparing the oncological outcomes of laparoscopic and open surgery in patients with Stage I/II colon and upper rectal cancers. *Surg Today*, 45(6), pp 700-7.

Numata, M., Sawazaki, S., Morita, J., Maezawa, Y., Amano, S., Aoyama, T., Sato, T., Oshima, T., Mushiake, H., Yukawa, N., Shiozawa, M., Rino, Y. & Masuda, M. 2018. Comparison of Laparoscopic and Open Surgery for Colorectal Cancer in Patients with Severe Comorbidities. *Anticancer Res*, 38(2), pp 963-967.

Rino, Y., Yukawa, N., Kano, K., Sato, T., Yamada, T., Aoyama, T., Maezawa, Y., Oshima, T., Shiozawa, M., Morinaga, S., Cho, H., Yoshikawa, T. & Masuda, M. 2018. Our connection procedure for an EEA XL stapler and anvil head using EEA OrVil for laparoscopic total or proximal gastrectomy. *Asian J Endosc Surg*, 11(3), pp 280-283.

Sawazaki, S., Numata, M., Morita, J., Maezawa, Y., Amano, S., Aoyama, T., Tamagawa, H., Sato, T., Oshima, T., Mushiake, H., Yukawa, N., Shiozawa, M., Rino, Y. & Masuda, M. 2018. Safety of Laparoscopic Surgery for Colorectal Cancer in Patients with Severe Comorbidities. *Anticancer Res*, 38(6), pp 3767-3772.

Segami, K., Aoyama, T., Kano, K., Maezawa, Y., Nakajima, T., Ikeda, K., Sato, T., Fujikawa, H., Hayashi, T., Yamada, T., Oshima, T., Yukawa, N., Rino, Y., Masuda, M., Ogata, T., Cho, H. &

Yoshikawa, T. 2017. Risk factors for severe weight loss at 1 month after gastrectomy for gastric cancer. *Asian J Surg*.

Tamagawa, A., Aoyama, T., Tamagawa, H., Ju, M., Komori, K., Maezawa, Y., Kano, K., Kazama, K., Murakawa, M., Atsumi, Y., Sawazaki, S., Hara, K., Numata, M., Sato, T., Yukawa, N., Masuda, M. & Rino, Y. 2019. Influence of Postoperative Pneumonia on Esophageal Cancer Survival and Recurrence. *Anticancer Res*, 39(5), pp 2671-2678.

Yamada, T., Jin, Y., Hasuo, K., Maezawa, Y., Kumazu, Y., Rino, Y. & Masuda, M. 2013. Chylorrhea following laparoscopy assisted distal gastrectomy with D1+ dissection for early gastric cancer: A case report. *Int J Surg Case Rep*, 4(12), pp 1173-5.

IV 参考論文（和文）

前澤, 幸., 佐藤, 勉., 神尾, 一., 瀬上, 顕., 中島, 哲., 青山, 徹., 利野, 靖., 尾形, 高., 長, 晴. & 吉川, 貴. 2016a. 集学的治療により根治手術を施行しえた,HER2 原発陰性/腹膜播種陽性の Stage IV 胃癌の 1 例. *日本消化器外科学会雑誌*, 49(9), pp 867-872.

前澤, 幸., 佐藤, 勉., 神尾, 一., 瀬上, 顕., 中島, 哲., 川邊, 泰., 白井, 順., 藤川, 寛., 青山, 徹., 林, 勉., 池田, 耕., 山田, 貴., 土田, 知., 山本, 直., 大島, 貴., 利野, 靖., 益田, 宗., 尾形, 高., 長, 晴. & 吉川, 貴. 2016b. 長期(6 年)生存中の胃癌術後小脳転移の 1 例. *癌と化学療法*, 43(10), pp 1286-1288.

前澤, 幸., 山内, 美., 佐藤, 勉., 林, 勉., 山本, 直., 大島, 貴., 湯川, 寛., 山中, 正., 吉川, 貴., 利野, 靖. & 益田, 宗. 2017a. 孤立性リンパ節転移切除 30 ヶ月後に原発巣が判明した十二指腸 neuroendocrine tumor の 1 切除例. *日本消化器外科学会雑誌*, 50(6), pp 429-436.

前澤, 幸., 青山, 徹., 森田, 順., 神尾, 一., 天野, 新., 澤崎, 翔., 沼田, 正., 林, 勉., 山田, 貴., 佐藤, 勉., 大島, 貴., 湯川, 寛., 吉川, 貴., 益田, 宗. & 利野, 靖. 2019. 胃癌に対する胃切除術 Billroth I 再建後の逆流症状にアコチアミド塩酸塩が著効した 1 例. *癌と化学療法*, 46(3), pp 595-597.

前澤, 幸., 長, 晴., 神尾, 一., 中島, 哲., 池田, 耕., 山田, 貴., 佐藤, 勉., 大島, 貴., 利野, 靖., 益田, 宗., 尾形, 高. & 吉川, 貴. 2017b. 腹腔鏡補助下幽門側胃切除 Roux-en-Y 再建後に生じた内ヘルニアを腹腔鏡下に修復した 1 例. *癌と化学療法*, 44(10), pp 932-934.

前澤, 幸., 林, 勉., 山本, 淳., 大西, 宙., 堀井, 伸., 井上, 広., 木村, 準., 高川, 亮., 牧野, 洋., 鈴木, 喜., 大島, 貴., 円谷, 彰., 利野, 靖., 國崎, 主. & 益田, 宗. 2015. 術後食道再発に少量

Weekly Docetaxel/Cisplatin 療法が有効であった食道浸潤胃癌の 1 例. *癌と化学療法*, 42(10), pp 1304-1306.

前澤, 幸., 林, 勉., 沼田, 正., 渥美, 陽., 神尾, 一., 片山, 雄., 青山, 徹., 福島, 忠., 蓮尾, 公., 白石, 龍., 松川, 博., 笠原, 彰., 玉川, 洋., 利野, 靖. & 益田, 宗. 2016c. 市中病院における腹腔鏡下低位前方切除術の安全性 多施設共同後向き検討. *癌と化学療法*, 43(12), pp 1696-1698.

前澤, 幸., 蓮尾, 公., 神, 康., 原, 健., 利野, 靖. & 益田, 宗. 2014. 腸閉塞を契機として診断された悪性腹膜中皮腫の 1 例. *日本臨床外科学会雑誌*, 75(9), pp 2591-2596.